著者

Maksymilian A. Brzezicki Lauren Celentano Maciej Ostrowski Arup Chakraborty

出版者

The Japanese Society of Clinical Neuropsychopharmacology

雑誌

Clinical Neuropsychopharmacology and Therapeutics (ISSN:18848826)

巻号頁・発行日

vol.11, pp.67-78, 2020-11-18 (Released:2020-11-18)

参考文献数

46

---

Generalised anxiety disorder (GAD) displays a variety of psychological and physical symptoms. These are difficult to rapidly control with currently available pharmacological options. This review summarises the evidence for an acute use of microbiological modification drugs targeting vagal nerve stimulation.A systematic search was conducted in Medline, Pubmed, and PschInfo for all pre-clinical and human studies concerning the use of Lactobacillus and Bifidobacterium in the treatment of GAD.Twenty-five studies were eligible for inclusion. In mice, modification therapy resulted in improved behaviour that was at least non-inferior to standard therapy (antidepressants). Brain histopathology revealed further anti-inflammatory and neuroprotective benefits. Vagotomy abolished the anti-GAD properties of the treatment.In humans, several species demonstrated significant reductions in palpitations, shortness of breath, headaches, flu-like symptoms, and abdominal pains vs. placebo within 4 to 12 weeks. B. bifidum, B. lactis, L. acidophilus and S. thermophiles showed alleviation of physical symptoms to population baseline when added to an antidepressant. No significant side effects were reported in the studies.As physical symptoms are typically the presenting medical complaint of GAD, there is potential to control the disease with the administration of bacteria-containing pharmaceutical agents as an adjunct to current antidepressant options.

著者

Shinji Sato Yoichi Kawanishi Masayuki Ide Noriko Sodeyama Hitoshi Takei

出版者

The Japanese Society of Clinical Neuropsychopharmacology

雑誌

Clinical Neuropsychopharmacology and Therapeutics (ISSN:18848826)

巻号頁・発行日

vol.10, pp.26-28, 2019-11-08 (Released:2019-11-08)

参考文献数

12

被引用文献数

1

---

Autism spectrum disorder (ASD) includes disturbances in communication, imagination, and social interaction. In individuals with ASD, selective mutism is a common symptom of a communication disability. Selective serotonin reuptake inhibitors (SSRIs) have been recommended to treat selective mutism, especially after psychosocial interventions fail. However, the mechanism and efficacy of SSRIs in treating selective mutism remain unclear. Here we report the case of an adult male with ASD whose selective mutism was improved by aripiprazole but not SSRIs. To the best of our knowledge, this is the first such case report. We believe that our patient's case highlights the value of differentiating between psychopathology and psychopharmacology when examining ASD symptoms.

著者

Takeshi Watanabe Kaoru Kawasaki Trang T.H Tu Takayuki Suga Shiori Sugawara Lou Mikuzuki Anna Miura Yukiko Shinohara Tatsuya Yoshikawa Miho Takenoshita Akira Toyofuku Takahiko Nagamine

出版者

The Japanese Society of Clinical Neuropsychopharmacology

雑誌

Clinical Neuropsychopharmacology and Therapeutics (ISSN:18848826)

巻号頁・発行日

vol.9, pp.12-14, 2018-04-10 (Released:2018-04-10)

参考文献数

5

被引用文献数

2 3

著者

Tsukasa Murata Yoshitaka Nobukuni

出版者

The Japanese Society of Clinical Neuropsychopharmacology

雑誌

Clinical Neuropsychopharmacology and Therapeutics (ISSN:18848826)

巻号頁・発行日

vol.11, pp.45-46, 2020-06-23 (Released:2020-06-23)

参考文献数

5

被引用文献数

1 3

著者

Kensuke Yoshimura Tasuku Hashimoto Yasunori Sato Aiko Sato Takashi Takeuchi Hiroyuki Watanabe Takeshi Terao Michiko Nakazato Masaomi Iyo

出版者

The Japanese Society of Clinical Neuropsychopharmacology

雑誌

Clinical Neuropsychopharmacology and Therapeutics (ISSN:18848826)

巻号頁・発行日

vol.9, pp.20-28, 2018-09-28 (Released:2018-09-28)

参考文献数

30

被引用文献数

4

---

Purpose: Pharmacological treatments with some anticonvulsants, including valproate, and lithium should be avoided where possible in childbearing-aged and pregnant women with epilepsy and bipolar disorder because they increase the risk of major congenital malformations. We surveilled real-world prescriptions of anticonvulsants and lithium in childbearing-aged female and male outpatients in Japan, using the first public National Insurance Claims Database of Japan.Methods: We performed a summary statistical analysis of the numbers of the most prescribed 11 anticonvulsants and lithium tablets in female and male outpatients aged 15-29 (younger childbearing age), 30-49 (older childbearing age), and >50 (non-childbearing age) years from April 2014 to March 2015. We determined the association between anticonvulsant or lithium use and sex at childbearing age, and the odds ratio (OR) and 95% confidence intervals (CIs) were estimated using logistic regression analysis.Results: Valproate (number of tablets = 273,135,937) was the most prescribed among the 12 investigated drugs, and 125,451,907 tablets were prescribed for women (younger, older, and non-childbearing ages, 19,296,528, 47,826,746, and 58,328,63, respectively), compared to 147,684,031 tablets for men (24,534,648, 57,229,981, and 65,919,402, respectively). Valproate prescription was only slightly lower in childbearing-aged women than in the same-aged men (i.e., 15-29 years of age, OR = 0.889 [95% CI, 0.888-0.890]; 30-49 years of age, OR = 0.944 [95% CI, 0.944-0.945]).Discussion: This study demonstrated valproate was highly prescribed for childbearing-aged women in Japan in 2014-2015. Physicians should prescribe valproate with considerable caution in girls and childbearing-aged women.